BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing BBP-418, a substrate supplementation therapy for the treatment of limb-girdle muscular dystrophy type 2i. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Current Quote*
Last: $34.700
Change: -0.630
Book: $8.933
Volume: 80,039

As Of: 01/17 13:04 ET
*Quotes delayed by 20min.

Graphs for BBIO


3 Month Graph


6 Month Graph


1 Year Graph